Financhill
Buy
77

FMS Quote, Financials, Valuation and Earnings

Last price:
$23.10
Seasonality move :
2.67%
Day range:
$23.05 - $23.27
52-week range:
$17.93 - $24.31
Dividend yield:
2.79%
P/E ratio:
18.90x
P/S ratio:
0.65x
P/B ratio:
0.89x
Volume:
160.9K
Avg. volume:
250.9K
1-year change:
20.79%
Market cap:
$13.5B
Revenue:
$21.1B
EPS (TTM):
$1.22

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
FMS
Fresenius Medical Care AG
$4.7B $0.47 -8.49% 263.66% $23.57
AFMD
Affimed NV
$1.3M -$0.57 -50.03% -42.4% $15.12
BNTX
BioNTech SE
$193.2M -$1.95 -24.68% -74.38% $137.63
CVAC
CureVac NV
$14.3M -$0.18 -71.66% -69.73% $7.30
IFRX
InflaRx NV
$49.5K -$0.32 5602.11% -2.23% $8.06
IMTX
Immatics NV
$22.1M -$0.22 -5.77% -3.64% $16.42
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
FMS
Fresenius Medical Care AG
$23.07 $23.57 $13.5B 18.90x $0.64 2.79% 0.65x
AFMD
Affimed NV
$1.15 $15.12 $18.9M -- $0.00 0% 18.62x
BNTX
BioNTech SE
$111.93 $137.63 $26.8B 191.55x $0.00 0% 8.18x
CVAC
CureVac NV
$4.10 $7.30 $919.8M 7.48x $0.00 0% 1.54x
IFRX
InflaRx NV
$2.54 $8.06 $149.6M -- $0.00 0% 810.37x
IMTX
Immatics NV
$5.35 $16.42 $650.3M -- $0.00 0% 4.29x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
FMS
Fresenius Medical Care AG
-- 0.039 -- 0.78x
AFMD
Affimed NV
31.93% 1.956 16.35% 1.76x
BNTX
BioNTech SE
1.26% 0.632 0.96% 7.10x
CVAC
CureVac NV
-- 1.506 -- 6.10x
IFRX
InflaRx NV
-- 3.548 -- 4.34x
IMTX
Immatics NV
-- 1.609 -- 3.87x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
FMS
Fresenius Medical Care AG
$1.3B $464.1M 3.22% 4.37% 10.08% --
AFMD
Affimed NV
-- -$15.7M -127.62% -158.94% -9594.22% -$13.2M
BNTX
BioNTech SE
$1.2B $11.5M -2.32% -2.35% 13.39% -$770.2M
CVAC
CureVac NV
$519.1M $404.1M 21.3% 21.3% 75.06% $381.2M
IFRX
InflaRx NV
$216K -$16.9M -61.55% -61.55% -14084.63% -$11.2M
IMTX
Immatics NV
-- $565.3K -16.88% -16.88% -4.19% -$42M

Fresenius Medical Care AG vs. Competitors

  • Which has Higher Returns FMS or AFMD?

    Affimed NV has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of -9767.12%. Fresenius Medical Care AG's return on equity of 4.37% beat Affimed NV's return on equity of -158.94%.

    Company Gross Margin Earnings Per Share Invested Capital
    FMS
    Fresenius Medical Care AG
    24.08% $0.40 $15.2B
    AFMD
    Affimed NV
    -- -$1.03 $28.2M
  • What do Analysts Say About FMS or AFMD?

    Fresenius Medical Care AG has a consensus price target of $23.57, signalling upside risk potential of 2.19%. On the other hand Affimed NV has an analysts' consensus of $15.12 which suggests that it could grow by 1214.51%. Given that Affimed NV has higher upside potential than Fresenius Medical Care AG, analysts believe Affimed NV is more attractive than Fresenius Medical Care AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    FMS
    Fresenius Medical Care AG
    1 3 1
    AFMD
    Affimed NV
    5 0 0
  • Is FMS or AFMD More Risky?

    Fresenius Medical Care AG has a beta of 0.925, which suggesting that the stock is 7.468% less volatile than S&P 500. In comparison Affimed NV has a beta of 2.168, suggesting its more volatile than the S&P 500 by 116.835%.

  • Which is a Better Dividend Stock FMS or AFMD?

    Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.79%. Affimed NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. Affimed NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios FMS or AFMD?

    Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than Affimed NV quarterly revenues of $170.5K. Fresenius Medical Care AG's net income of $234.3M is higher than Affimed NV's net income of -$16.7M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.90x while Affimed NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.65x versus 18.62x for Affimed NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FMS
    Fresenius Medical Care AG
    0.65x 18.90x $5.2B $234.3M
    AFMD
    Affimed NV
    18.62x -- $170.5K -$16.7M
  • Which has Higher Returns FMS or BNTX?

    BioNTech SE has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of 15.91%. Fresenius Medical Care AG's return on equity of 4.37% beat BioNTech SE's return on equity of -2.35%.

    Company Gross Margin Earnings Per Share Invested Capital
    FMS
    Fresenius Medical Care AG
    24.08% $0.40 $15.2B
    BNTX
    BioNTech SE
    85.63% $0.89 $21.6B
  • What do Analysts Say About FMS or BNTX?

    Fresenius Medical Care AG has a consensus price target of $23.57, signalling upside risk potential of 2.19%. On the other hand BioNTech SE has an analysts' consensus of $137.63 which suggests that it could grow by 22.97%. Given that BioNTech SE has higher upside potential than Fresenius Medical Care AG, analysts believe BioNTech SE is more attractive than Fresenius Medical Care AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    FMS
    Fresenius Medical Care AG
    1 3 1
    BNTX
    BioNTech SE
    12 5 0
  • Is FMS or BNTX More Risky?

    Fresenius Medical Care AG has a beta of 0.925, which suggesting that the stock is 7.468% less volatile than S&P 500. In comparison BioNTech SE has a beta of 0.182, suggesting its less volatile than the S&P 500 by 81.764%.

  • Which is a Better Dividend Stock FMS or BNTX?

    Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.79%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios FMS or BNTX?

    Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than BioNTech SE quarterly revenues of $1.4B. Fresenius Medical Care AG's net income of $234.3M is higher than BioNTech SE's net income of $217.9M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.90x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.65x versus 8.18x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FMS
    Fresenius Medical Care AG
    0.65x 18.90x $5.2B $234.3M
    BNTX
    BioNTech SE
    8.18x 191.55x $1.4B $217.9M
  • Which has Higher Returns FMS or CVAC?

    CureVac NV has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of 68.44%. Fresenius Medical Care AG's return on equity of 4.37% beat CureVac NV's return on equity of 21.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    FMS
    Fresenius Medical Care AG
    24.08% $0.40 $15.2B
    CVAC
    CureVac NV
    95.56% $1.65 $809.4M
  • What do Analysts Say About FMS or CVAC?

    Fresenius Medical Care AG has a consensus price target of $23.57, signalling upside risk potential of 2.19%. On the other hand CureVac NV has an analysts' consensus of $7.30 which suggests that it could grow by 78.16%. Given that CureVac NV has higher upside potential than Fresenius Medical Care AG, analysts believe CureVac NV is more attractive than Fresenius Medical Care AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    FMS
    Fresenius Medical Care AG
    1 3 1
    CVAC
    CureVac NV
    3 2 0
  • Is FMS or CVAC More Risky?

    Fresenius Medical Care AG has a beta of 0.925, which suggesting that the stock is 7.468% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock FMS or CVAC?

    Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.79%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios FMS or CVAC?

    Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than CureVac NV quarterly revenues of $543.2M. Fresenius Medical Care AG's net income of $234.3M is lower than CureVac NV's net income of $371.8M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.90x while CureVac NV's PE ratio is 7.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.65x versus 1.54x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FMS
    Fresenius Medical Care AG
    0.65x 18.90x $5.2B $234.3M
    CVAC
    CureVac NV
    1.54x 7.48x $543.2M $371.8M
  • Which has Higher Returns FMS or IFRX?

    InflaRx NV has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of -14092.9%. Fresenius Medical Care AG's return on equity of 4.37% beat InflaRx NV's return on equity of -61.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    FMS
    Fresenius Medical Care AG
    24.08% $0.40 $15.2B
    IFRX
    InflaRx NV
    -5376.61% -$0.33 $72.9M
  • What do Analysts Say About FMS or IFRX?

    Fresenius Medical Care AG has a consensus price target of $23.57, signalling upside risk potential of 2.19%. On the other hand InflaRx NV has an analysts' consensus of $8.06 which suggests that it could grow by 217.29%. Given that InflaRx NV has higher upside potential than Fresenius Medical Care AG, analysts believe InflaRx NV is more attractive than Fresenius Medical Care AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    FMS
    Fresenius Medical Care AG
    1 3 1
    IFRX
    InflaRx NV
    3 1 0
  • Is FMS or IFRX More Risky?

    Fresenius Medical Care AG has a beta of 0.925, which suggesting that the stock is 7.468% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.657, suggesting its more volatile than the S&P 500 by 65.659%.

  • Which is a Better Dividend Stock FMS or IFRX?

    Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.79%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios FMS or IFRX?

    Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than InflaRx NV quarterly revenues of $136.2K. Fresenius Medical Care AG's net income of $234.3M is higher than InflaRx NV's net income of -$19.2M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.90x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.65x versus 810.37x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FMS
    Fresenius Medical Care AG
    0.65x 18.90x $5.2B $234.3M
    IFRX
    InflaRx NV
    810.37x -- $136.2K -$19.2M
  • Which has Higher Returns FMS or IMTX?

    Immatics NV has a net margin of 4.48% compared to Fresenius Medical Care AG's net margin of -16.95%. Fresenius Medical Care AG's return on equity of 4.37% beat Immatics NV's return on equity of -16.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    FMS
    Fresenius Medical Care AG
    24.08% $0.40 $15.2B
    IMTX
    Immatics NV
    -- -$0.12 $427.2M
  • What do Analysts Say About FMS or IMTX?

    Fresenius Medical Care AG has a consensus price target of $23.57, signalling upside risk potential of 2.19%. On the other hand Immatics NV has an analysts' consensus of $16.42 which suggests that it could grow by 206.85%. Given that Immatics NV has higher upside potential than Fresenius Medical Care AG, analysts believe Immatics NV is more attractive than Fresenius Medical Care AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    FMS
    Fresenius Medical Care AG
    1 3 1
    IMTX
    Immatics NV
    5 0 0
  • Is FMS or IMTX More Risky?

    Fresenius Medical Care AG has a beta of 0.925, which suggesting that the stock is 7.468% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.769%.

  • Which is a Better Dividend Stock FMS or IMTX?

    Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.79%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 65.86% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios FMS or IMTX?

    Fresenius Medical Care AG quarterly revenues are $5.2B, which are larger than Immatics NV quarterly revenues of $55.6M. Fresenius Medical Care AG's net income of $234.3M is higher than Immatics NV's net income of -$9.4M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 18.90x while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.65x versus 4.29x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FMS
    Fresenius Medical Care AG
    0.65x 18.90x $5.2B $234.3M
    IMTX
    Immatics NV
    4.29x -- $55.6M -$9.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is AT&T Stock Dropping?
Why Is AT&T Stock Dropping?

The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…

Is American Express Stock Going Lower?
Is American Express Stock Going Lower?

American Express Company (NYSE:AXP) has long been a Buffett favorite…

Cigna vs Costco Stock: Which Is Best?
Cigna vs Costco Stock: Which Is Best?

Cigna and Costco don’t usually go hand in hand but…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
45
QMCO alert for Jan 18

Quantum [QMCO] is down 15.61% over the past day.

Buy
51
QRVO alert for Jan 18

Qorvo [QRVO] is up 14.47% over the past day.

Sell
31
ATEX alert for Jan 18

Anterix [ATEX] is up 11.14% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock